- Home
- ETV vs ANIP Comparison
ETV vs ANIP Comparison
Compare ETV & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETV
- ANIP
- Stock Information
- Founded
- ETV 2005
- ANIP 2001
- Country
- ETV United States
- ANIP United States
- Employees
- ETV N/A
- ANIP N/A
- Industry
- ETV Investment Managers
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- ETV Finance
- ANIP Health Care
- Exchange
- ETV Nasdaq
- ANIP Nasdaq
- Market Cap
- ETV 1.6B
- ANIP 1.4B
- IPO Year
- ETV N/A
- ANIP N/A
- Fundamental
- Price
- ETV $14.06
- ANIP $89.69
- Analyst Decision
- ETV
- ANIP Strong Buy
- Analyst Count
- ETV 0
- ANIP 9
- Target Price
- ETV N/A
- ANIP $82.89
- AVG Volume (30 Days)
- ETV 252.5K
- ANIP 621.8K
- Earning Date
- ETV 01-01-0001
- ANIP 08-08-2025
- Dividend Yield
- ETV 8.75%
- ANIP N/A
- EPS Growth
- ETV N/A
- ANIP N/A
- EPS
- ETV N/A
- ANIP N/A
- Revenue
- ETV N/A
- ANIP $747,399,000.00
- Revenue This Year
- ETV N/A
- ANIP $31.40
- Revenue Next Year
- ETV N/A
- ANIP $7.38
- P/E Ratio
- ETV N/A
- ANIP N/A
- Revenue Growth
- ETV N/A
- ANIP 38.68
- 52 Week Low
- ETV $11.05
- ANIP $52.50
- 52 Week High
- ETV $13.50
- ANIP $90.23
- Technical
- Relative Strength Index (RSI)
- ETV 65.99
- ANIP 84.59
- Support Level
- ETV $13.90
- ANIP $62.61
- Resistance Level
- ETV $14.05
- ANIP $90.23
- Average True Range (ATR)
- ETV 0.12
- ANIP 3.16
- MACD
- ETV 0.02
- ANIP 2.59
- Stochastic Oscillator
- ETV 90.53
- ANIP 93.52
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.